newsfilter
← Earnings
Earnings Releases·

Pulse Biosciences — Third Quarter 2026 Earnings Summary

Pulse Biosciences completed enrollment in its U.S. pivotal NANOPULSE-AF IDE study for atrial fibrillation treatment in under six months, finishing three months ahead of schedule. The company reported third-quarter 2026 total revenue of $0.4 million and a GAAP net loss of $23.1 million, while raising $95.8 million in net proceeds through ATM programs to bolster its cash position to $189.2 million. In addition to the cardiac catheter progress, the firm advanced enrollment in the NANOCLAMP-AF surgical study and the PRECISE-BTN thyroid nodule study, with plans to submit a persistent AF IDE application in the fourth quarter of 2026.

Company
PULSE BIOSCIENCES INC
Sector
Healthcare
Industry
Medical Instruments & Supplies